Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Visit

EBMT 2018 | The IMPACT Partnership: Improving regulation and turnaround of transplant clinical trials

Charles Craddock • 18 Mar 2018

EBMT 2018

Acute Myeloid Leukemia Leukemia CPX-351 Cytarabine Daunorubicin

There is a desperate need for rapid turnaround of transplant clinical trials to bring forward breakthrough therapies. IMPACT is a new partnership that aims to improve regulation and transplant outcomes. Speaking here, Charles Craddock, CBE, FRCP (UK), FRCPath, DPhil, from University Hospitals Birmingham NHS Foundation Trust, Birmingham, UK, introduces key trials that will be starting soon, including the PRO-DLI trial (NCT02856464), a trial investigating CPX-351 for untreated acute myeloid leukemia (NCT03335267). This video was recorded at the 2018 European Society for Blood and Marrow Transplantation (EBMT) Annual Meeting in Lisbon, Portugal.

Addressing the high rate of disease relapse following alloSCT in patients with AML

Charles Craddock • 10 Dec 2023

Stem cell transplantation conditioning in AML: making the decision between MAC and RIC

Charles Craddock • 10 Dec 2023

The UK Impact Transplant Trials Network: a national strategy to accelerate delivery of alloSCT RCTs

Charles Craddock • 10 Dec 2023

Transplantation & immunotherapies

Charles Craddock et al. • 4 Sep 2023

Related Videos

The role of CPX-351 in the AML treatment landscape & insights into the AMLSG 30-18 trial

Felicitas Thol • 19 Apr 2024

Integrating genomics and MRD in transplant decision-making for patients with AML

Jurjen Versluis • 22 Apr 2024

Blinatumomab to achieve remission and consolidation with haploSCT for pediatric ALL

Alberto Olaya-Vargas • 15 Apr 2024

Improving CAR-T therapy for ALL & lymphoma: allogeneic products & reducing CRS/ICANS

Sridhar Chaganti • 16 Apr 2024